1. Trial profile Prakash Deedwania, et al. Lancet 2006; 368: 919-28

2. Baseline characteristics of patients with metabolic syndrome Prakash Deedwania, et al. Lancet 2006; 368: 919-28

3. Mean lipid levels after randomisation in all patients with metabolic syndrome Prakash Deedwania, et al. Lancet 2006; 368: 919-28

4. Kaplan-Meier estimates of the proportion of patients with major cardiovascular events by treatment in all patients with metabolic syndrome and in patients with metabolic syndrome without diabetes Prakash Deedwania, et al. Lancet 2006; 368: 919-28

5. Hazard ratios for primary and secondary outcomes in all patients recruited in the TNT study (n=10001), all patients with metabolic syndrome (n=5584), and patients with metabolic syndrome without diabetes (n=4353) Prakash Deedwania, et al. Lancet 2006; 368: 919-28

6. Kaplan-Meier estimates of prevalence of patients with major cardiovascular events in all TNT patients by metabolic syndrome and diabetes status Prakash Deedwania, et al. Lancet 2006; 368: 919-28

7. Univariate analysis of individual characteristics of metabolic syndrome on risk of major cardiovascular events in all TNT patients (n=10001) Prakash Deedwania, et al. Lancet 2006; 368: 919-28 HR=hazard ratio. HDL-C=high density lipoprotein cholesterol Numbers in parentheses represent 95% CI *p<0·0001. †p=0·0009. ‡p=0·015

8. Number of patients with major cardiovascular events by presence of metabolic syndrome components in (A) all TNT patients (n=10001), and (B) all TNT patients without diabetes (n=8500) Prakash Deedwania, et al. Lancet 2006; 368: 919-28 HR=hazard ratio. Numbers in parentheses represent 95% CI. Atv=atorvastatin